Condition: B-cell Acute Lymphoblastic Leukemia · Lymphoblastic B-Cell Lymphoma · Sponsor: Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
The purpose of this study is to estimate the safety and the efficacy of CAR- T cells immunotherapy for children/young adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma.
This description comes directly from the study's public registry record.
Elena Lukoyko, MD · +375291643075 · lenalukojko@gmail.com
Aleksandr Meleshko, PhD · +375296940023 · meleshko@tut.by
Always discuss trial participation with your own doctor first.
| Belarussian Research Center for Pediatric Oncology, Hematology and Immunology | Minsk, Minsk Oblast, Belarus | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05333302